Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Autotelic Bio Inc. logo — RNA Therapeutics New Drug Development Company

Autotelic Bio Inc.

RNA Therapeutics New Drug Development Company

Founded 2015 Korea South Korea South 15 employees Series B Total: $22.00B Biotechnology, Pharmaceutical

General Information

Company Name Autotelic Bio Inc.
Founded Year 2015
Location Korea South Korea South +2
Employees 15
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Social

Get notified when Autotelic Bio Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Autotelic Bio Inc.

Autotelic Bio Inc., a **clinical stage pharmaceutical company** founded in **2015** in **South Korea**, is making strides in the field of RNA therapeutics. The company's proprietary RNA interference (RNAi) ASO platform, **ASODE & CATs (Conjugated ASO Targeting Solution)**, sets it apart by enabling selective targeting and precise optimization of Antisense Oligonucleotide (ASO) therapies. This innovative approach holds the promise of delivering greater efficacy, safety, and tolerability compared to other RNAi medicines. With a focus on **Immuno-oncology, IPF**, and the development of **FDCs with synergy effect**, Autotelic Bio is positioning itself as a key player in tackling pressing medical needs. The company recently secured a substantial **KRW15.50B Series B investment** on **28 March 2022**, with notable investors including **Stonebridge Ventures, UTC 2019 BioVentureFund, LSK Investment, Sejong Venture Partners, Woori Bank, JB Ventures,** and **DT Investments**. Autotelic Bio Inc.'s commitment to advancing RNA therapeutics and its impressive funding round make it a company to watch in the biotechnology and pharmaceutical industries.

Taxonomy: RNA therapeutics, drug development, pharmaceutical company, clinical stage, nucleic acid therapies, RNA interference (RNAi), ASO platform, immuno-oncology, IPF, FDCs, antisense oligonucleotide, therapeutic targeting, precision medicine, biopharmaceuticals, clinical trials

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		28 Mar 2022
Series A •••••• 2
Investor
•••• •••• 		14 Dec 2020
Series A •••••• 1
Investor
01 Jul 2020

Autotelic Bio Inc. Alternatives & Competitors

Autotelic Bio Inc. vs
Genome Biologics
Genome Biologics

Genome Biologics develops RNAi therapies for cardiovascular and cardiometabolic disease, targeting s...

Autotelic Bio Inc. vs
Suzhou Ribo Life Science Co., Ltd
Suzhou Ribo Life Science Co., Ltd China

Dedicated to Innovative Oligonucleotide Therapeutics to Improve Human Health and Wellbeing

Series C
21 employees
Biotechnology
Autotelic Bio Inc. vs
OliX Pharmaceuticals, Inc.
OliX Pharmaceuticals, Inc. Korea South

Contributing to the Health and Happiness of Mankind with RNAi Technology

Post Ipo Equity
38 employees
Biotechnology, Pharmaceutical
Also compare with: Autotelic Bio Inc. vs SanegeneBio SanegeneBio

FAQ About Autotelic Bio Inc.

RNA Therapeutics New Drug Development Company
Autotelic Bio Inc. was founded in 2015.
Autotelic Bio Inc. is headquartered in Korea South.
Autotelic Bio Inc. operates in the following industries: Biotechnology, Pharmaceutical.
Autotelic Bio Inc. has approximately 15 employees.
Autotelic Bio Inc. has completed 3 funding rounds, raising a total of $22.00B. The latest funding stage is Series B.
Top alternatives and competitors to Autotelic Bio Inc. include Genome Biologics, Suzhou Ribo Life Science Co., Ltd, OliX Pharmaceuticals, Inc., SanegeneBio, Phio Pharmaceuticals Corp.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Autotelic Bio Inc. and Genome Biologics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Autotelic Bio Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy